Published in Curr Infect Dis Rep on February 01, 2004
Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis (2005) 1.74
Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis (2005) 1.68
Children with pneumonia: how do they present and how are they managed? Arch Dis Child (2007) 1.03
Human antimicrobial peptide LL-37 induces MefE/Mel-mediated macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2010) 0.94
Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis (2006) 0.93
In vitro activities of novel 2-fluoro-naphthyridine-containing ketolides. Antimicrob Agents Chemother (2005) 0.81
Telithromycin-resistant Streptococcus pneumoniae. Emerg Infect Dis (2005) 0.80
Use of the respiratory fluoroquinolones for the outpatient management of community-acquired pneumonia. Curr Ther Res Clin Exp (2004) 0.75
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med (2001) 9.08
Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother (1996) 8.65
Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis (2000) 7.80
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother (1991) 7.18
New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) (1990) 4.04
Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group. J Infect Dis (1991) 4.00
The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother (2003) 3.61
Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis (2002) 3.48
Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA (2001) 2.40
Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis (2002) 2.26
Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis (2000) 1.89
National Ambulatory Medical Care Survey: 2001 summary. Adv Data (2003) 1.83
Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med (2002) 1.81
Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study. Antimicrob Agents Chemother (2003) 1.78
Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother (2003) 1.73
Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J (2000) 1.57
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis (2003) 1.42
High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. Antimicrob Agents Chemother (1993) 1.39
Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother (2000) 1.28
Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia. Antimicrob Agents Chemother (2002) 1.20
Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis (2000) 1.09
Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother (2001) 0.97
Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr Infect Dis J (1996) 0.94
In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models. Antimicrob Agents Chemother (2001) 0.91
Etiology of community-acquired pneumonia. Evaluation by transtracheal aspiration, blood culture, or serology. Chest (1993) 0.90
Meningitis and pneumonia due to novel multiply resistant pneumococci. Br Med J (Clin Res Ed) (1986) 0.89
Fatal pneumococcal pneumonia attributed to macrolide resistance and azithromycin monotherapy. Chest (2000) 0.88
In vivo efficacy of telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob Agents Chemother (2001) 0.88
Streptococcus pneumoniae resistant to erythromycin and clindamycin. J Pediatr (1978) 0.86
Macrolide-resistant pneumococcal endocarditis and epidural abscess that develop during erythromycin therapy. Clin Infect Dis (2003) 0.83
Pneumonia caused by a pneumococcus resistant to erythromycin and lincomycin. Case report. Mo Med (1974) 0.79
Penicillin-resistant pneumococci and community-acquired pneumonia. Lancet (1992) 0.78